Cognitive Therapeutics $3.3 Million Alzheimer's Trial Grant - CEO, Ken Moch

Larry Richert and John Shumway
Thursday, July 11th
Cognitive Therapeutics CEO Ken Moch joins Larry and John to discuss the $3.3 million Alzheimer's Trial Grant.  He explains how quantitative electroencephalography will be used to measure changes in Alzheimer's patients synaptic activity. 
00:05:08